免疫调节药物众多:免疫介导肾脏疾病的治疗机遇
本综述聚焦免疫介导肾脏疾病,梳理了针对适应性免疫(T细胞活化与信号异常、B细胞功能异常)和固有免疫(补体与髓系系统)以及组织修复与纤维化病理通路的靶向治疗进展。文中提及利妥昔单抗和阿伐可泮已获批用于免疫介导肾脏疾病,并讨论了现有药物重定位策略、正在开展的临床试验及未来可靶向的通路。
要点
- 利妥昔单抗和阿伐可泮已获批用于免疫介导肾脏疾病的治疗。
- 适应性免疫(T细胞活化与信号异常、B细胞功能异常)在疾病中具有重要性。
- 固有免疫(补体与髓系系统)及组织修复与纤维化病理反应在疾病中起关键作用。
核心结论
- 针对固有免疫和适应性免疫的机制研究为免疫介导肾脏疾病的肾小球损伤机制提供了新见解。
- 多种自身免疫病共有的炎症通路提示,将现有药物重定位用于免疫介导肾脏疾病是合理策略。
研究设计与样本
- 综述,聚焦针对免疫介导肾脏疾病作为主要适应症的免疫调节疗法的临床试验与未来可靶向通路。
主要发现
- 利妥昔单抗和阿伐可泮已获批用于免疫介导肾脏疾病的治疗。
- 免疫介导肾脏疾病的新药研发落后于更常见的自身免疫病。
- 适应性免疫异常包括T细胞活化与信号异常以及B细胞功能异常。
- 固有免疫中补体和髓系系统以及组织修复与纤维化病理反应在疾病中起关键作用。
临床怎么用
- 综述强调将新的机制认识转化为新型疗法以改善疾病结局。
- 综述详细介绍了正在开展的临床试验及未来可靶向的通路。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In recent decades, insights into the molecular pathways involved in disease have revolutionized the treatment of autoimmune diseases. A plethora of targeted therapies have been identified and are at varying stages of clinical development in renal autoimmunity. Some of these agents, such as rituximab or avacopan, have been approved for the treatment of immune-mediated kidney disease, but kidney disease lags behind more common autoimmune disorders in new drug development. Evidence is accumulating as to the importance of adaptive immunity, including abnormalities in T-cell activation and signaling, and aberrant B-cell function. Furthermore, innate immunity, particularly the complement and myeloid systems, as well as pathologic responses in tissue repair and fibrosis, play a key role in disease. Collectively, these mechanistic studies in innate and adaptive immunity have provided new insights into mechanisms of glomerular injury in immune-mediated kidney diseases. In addition, inflammatory pathways common to several autoimmune conditions exist, suggesting that the repurposing of some existing drugs for the treatment of immune-mediated kidney diseases is a logical strategy. This new understanding challenges the clinical investigator to translate new knowledge into novel therapies leading to better disease outcomes. This review highlights promising immunomodulatory therapies tested for immune-mediated kidney diseases as a primary indication, details current clinical trials and discusses pathways that could be targeted in the future.
引用
- Odler B, Tieu J, Artinger K, et al. The plethora of immunomodulatory drugs: opportunities for immune-mediated kidney diseases. Nephrol Dial Transplant. 2023. PMID: 37816674. doi:10.1093/ndt/gfad186
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。